The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Apolipoprotein E Type 4 Allele and Cerebral Glucose Metabolism in Relatives at Risk for Familial Alzheimer Disease
Abstract
OBJECTIVE: Cerebral parietal hypometabolism and left-right asymmetry occur early in the course of Alzheimer disease (AD), and the apolipoprotein E type 4 allele (APOE epsilon 4) is a risk factor for familial AD. To determine if APOE epsilon 4 is associated with lowered brain function in nondemented relatives at risk for familial AD, we studied 12 relatives with APOE epsilon 4 and 19 relatives without APOE epsilon 4. We also compared them with seven patients with probable AD. DESIGN: After grouping subjects according to diagnosis and genotype, brain function measures were compared among groups. SETTING: University medical center. PATIENTS: At risk subjects had mild memory complaints, normal cognitive performance, and at least two relatives with AD. Subjects with APOE epsilon 4 did not differ from those without APOE epsilon 4 in mean age at examination (56.4 vs 55.5 years) or in neuropsychological performance (mean Mini-Mental State Examination score, 28.8 vs 29.3). MAIN OUTCOME MEASURES: Cerebral glucose metabolism was measured using positron emission tomography and fludeoxyglucose F 18. RESULTS: Parietal metabolism was significantly lower and left-right parietal asymmetry was significantly higher in at-risk subjects with APOE epsilon 4 compared with those without APOE epsilon 4. Patients with dementia had significantly lower parietal metabolism than did at-risk subjects with APOE epsilon 4. CONCLUSIONS: These results suggest that the inheritance of APOE epsilon 4 is associated with reduced cerebral parietal metabolism and increased asymmetry in non-demented relatives at risk for probable AD. Longitudinal study will determine if glucose metabolic measures provide a means to monitor experimental treatment responses during the early phases of the disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, both cross-sectional (21, 22) and longitudinal PET studies (23) show that nondemented E4 carriers have more hypometabolic regions than controls, but a relationship to longitudinally observed decline has not been reported.”
From Prediction of cognitive decline in normal elderly subjects with 2-[ 18 F]fluoro-2-deoxy- d -glucose/positron-emission tomography (FDG/PET) (2001) · cites this paper as [21]
In the citing paper
“It has been suggested that this association may account for the earlier onset of symptoms in E4 carriers (21–23).”
From Prediction of cognitive decline in normal elderly subjects with 2-[ 18 F]fluoro-2-deoxy- d -glucose/positron-emission tomography (FDG/PET) (2001) · cites this paper as [21]
In the citing paper
“In a recent study, subjects with the apolipoprotein E e 3/ e 4 genotype, age-associated memory impairment, and a family history of Alzheimer's disease had abnormally low and asymmetric rates of glucose metabolism in a preselected parietal region before the onset of dementia.15”
From Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the ε4 Allele for Apolipoprotein E (1996) · cites this paper as [15]
In the citing paper
“Case series suggest that abnormalities in glucose metabolism can be detected by PET before substantial impairment occurs in persons at risk for Alzheimer's disease [14][15][16]”
From Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the ε4 Allele for Apolipoprotein E (1996) · cites this paper as [15]
In the citing paper
“Our hypothesis, therefore, can accommodate a growing realization that for many subjects with suspected AD, or who have an increased risk of developing AD, what are currently considered downstream biomarker changes potentially precede upstream biomarker changes [206-213].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [210]
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Phelps, M. E., Huang, S. C., Hoffman, E. J., Selin, C. E., Sokoloff, L., & Kuhl, D. E. (1979) · Annals of Neurology · doi:10.1002/ana.410060502 · Cited by 2,417
Cited by
Sorted by citations
Items 101–162 of 162
M OLECULAR I MAGING WITH P OSITRON E MISSION T OMOGRAPHY
Phelps, M. E. (2002) · Annual Review of Nuclear and Particle Science · doi:10.1146/annurev.nucl.52.050102.090725 · Cited by 39
Neurotrophins and Alzheimer's disease: Beyond the cholinergic neurons
Knüsel, B., & Gao, H. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00193-2 · Cited by 39
Alzheimer’s disease and frontotemporal dementia exhibit distinct atrophy-behavior correlates
Gee, J. C., Ding, L., Xie, Z., Lin, M., DeVita, C., & Grossman, M. (2003) · Academic Radiology · doi:10.1016/s1076-6332(03)00543-9 · Cited by 37
Emission tomography contribution to clinical neurology
Iacoboni, M., Baron, J., Frackowiak, R. S. J., Mazziotta, J. C., & Lenzi, G. L. (1999) · Clinical Neurophysiology · doi:10.1016/s0013-4694(98)00097-2 · Cited by 38
H. Swerdlow, R. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072535 · Cited by 35
van Dyck, C. H., Gelernter, J. E., MacAvoy, M. G., Avery, R. A., Criden, M., Okereke, O. I., Varma, P., Seibyl, J. P., & Hoffer, P. B. (1998) · Archives of Neurology · doi:10.1001/archneur.55.11.1460 · Cited by 30
Amyloid PET Ligands for Dementia
Villemagne, V. L., & Rowe, C. C. (2010) · PET Clinics · doi:10.1016/j.cpet.2009.12.008 · Cited by 31
Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer's disease
Mielke, R., Zerres, K., Uhlhaas, S., Kessler, J., & Heiß, W.-D. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00673-9 · Cited by 29
Verwer, R. W. H., Jansen, K. A., Sluiter, A. A., Pool, C. W., Kamphorst, W., & Swaab, D. F. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7385 · Cited by 28
Bartrés‐Faz, D., Serra-Grabulosa, J. M., Sun, F. T., Solé‐Padullés, C., Rami, L., Molinuevo, J. L., Bosch, B., Mercader, J. M., Bargalló, N., Falcón, C., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.021 · Cited by 25
Neuroimaging: Technologies at the Interface of Genes, Brain, and Behavior
Bigos, K. L., & Hariri, A. R. (2007) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2007.09.005 · Cited by 24
Positron Emission Tomography Imaging in Dementia
Herholz, K. (2008) · European Neurological Review · doi:10.17925/enr.2008.03.02.109 · Cited by 21
Midlife Lifestyle Activities Moderate APOE ε4 Effect on in vivo Alzheimer’s Disease Pathologies
Jeon, S. Y., Byun, M. S., Yi, D., Lee, J., Ko, K., Sohn, B. K., Lee, J., Ryu, S., Lee, D. W., Shin, S. A., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00042 · Cited by 24
Use of neuroimaging to detect early brain changes in people at genetic risk for Alzheimer’s disease
Small, G. W. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00151-5 · Cited by 24
Self-citationApostolova, L. G., Thompson, P. M., Rogers, S., Dinov, I. D., Zoumalan, C., Steiner, C. A., Siu, E., Green, A. E., Small, G. W., Toga, A. W., et al. (2009) · Molecular Imaging and Biology · doi:10.1007/s11307-009-0247-7 · Cited by 21
Self-citationDecline in Learning Ability Best Predicts Future Dementia Type: The Freedom House Study
Royall, D. R., Palmer, R. F., Chiodo, L. K., & Polk, M. J. (2003) · Experimental Aging Research · doi:10.1080/03610730303700 · Cited by 20
Tröster, A. I., Fields, J. A., Paolo, A. M., & Koller, W. C. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.05.032 · Cited by 20
O'Hara, R. M., Sommer, B. R., Way, N., KRAEMER, H. C., Taylor, J. L., & Murphy, G. M. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.12.001 · Cited by 24
Reiman, E. M., & Caselli, R. J. (1999) · Maturitas · doi:10.1016/s0378-5122(98)00110-8 · Cited by 24
Lee, K. U., Lee, J. S., Kim, K. W., Jhoo, J. H., Lee, D. Y., Yoon, J. C., Lee, H., Lee, D. S., Lee, M. C., & Woo, J. I. (2003) · Journal of Neuropsychiatry · doi:10.1176/jnp.15.1.78 · Cited by 15
SINGLE PHOTON EMISSION CT AND POSITRON EMISSION TOMOGRAPHY IN THE EVALUATION OF NEUROLOGIC DISEASE
Heertum, R. L. V., DROCEA, C. W., Ichise, M., Lobotesis, K., & Fawwaz, R. A. (2001) · Radiologic Clinics of North America · doi:10.1016/s0033-8389(05)70326-2 · Cited by 15
Barć, K., & Kuźma‐Kozakiewicz, M. (2019) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2019.0013 · Cited by 15
Apolipoprotein ɛ4 and neuropsychological performance in Alzheimer's disease and vascular dementia
McGuinness, B., Carson, R., Barrett, S., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.07.063 · Cited by 12
The concept of FDG-PET endophenotype in Alzheimer’s disease
During, E., Osorio, R. S., Elahi, F. M., Mosconi, L., & de Leon, M. J. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0633-1 · Cited by 14
Positron Emission Tomography Diagnosis of Alzheimer's Disease
Coleman, R. E. (2007) · PET Clinics · doi:10.1016/j.cpet.2007.09.003 · Cited by 12
ApoE-epsilon4 Allele and Susceptibility to Drug-Induced Memory Impairment in the Elderly
Pomara, N., Tun, H., Deptula, D., & Greenblatt, D. J. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199804000-00017 · Cited by 10
Campion, E. W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341209 · Cited by 10
Morphologische und funktionelle Bildgebung
Schröder, J., & Pantel, J. (1999) · Springer eBooks · doi:10.1007/978-3-642-60228-3_8 · Cited by 10
Asymmetry of SPECT Perfusion Image Patterns as a Diagnostic Feature for Alzheimer’s Disease
Kovalev, V. A., Thurfjell, L., Lundqvist, R., et al. (2006) · Lecture notes in computer science · doi:10.1007/11866763_52 · Cited by 8
Evaluation of Early Dementia (Mild Cognitive Impairment)
Osorio, R. S., Berti, V., Mosconi, L., Li, Y., Glodzik, L., Santi, S. D., & de Leon, M. J. (2010) · PET Clinics · doi:10.1016/j.cpet.2009.12.003 · Cited by 5
Neuroimaging of Alzheimer’s Disease, Mild Cognitive Impairment, and Other Dementias
Risacher, S. L., & Saykin, A. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6373-4_19 · Cited by 5
Metabolomics: A New Approach Towards Identifying Biomarkers and Therapeutic Targets in CNS Disorders
Kaddurah-Daouk, R. F., Kristal, B. S., Bogdanov, M., et al. (2005) · Springer eBooks · doi:10.1007/0-387-25240-1_4 · Cited by 4
Diagnosis of Alzheimer's Disease
Morris, J. C. (1996) · Informa Healthcare eBooks · doi:10.1201/9781420048407.ch7 · Cited by 4
Neuroimaging in Alzheimer Disease
Kantarci, K., & Jack, C. R. (2006) · Springer eBooks · doi:10.1007/0-387-31216-1_8 · Cited by 3
Magistretti, P. J., Bittar, P. G., & Pellerin, L. (1997) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-4116-4_18 · Cited by 3
Update on the Development of Medication for Memory and Cognition in Alzheimer's Disease
Kumar, V., & Cantillon, M. (1996) · Psychiatric Annals · doi:10.3928/0048-5713-19960501-09 · Cited by 3
Mitochondrial Function and Neurodegenerative Diseases
Wilkins, H. M., Weidling, I., Koppel, S., Wang, X., von Schulze, A., & Swerdlow, R. H. (2018) · The Molecular and Cellular Basis of Neurodegenerative Diseases · doi:10.1016/b978-0-12-811304-2.00013-4 · Cited by 2
Herholz, K. (2008) · Springer eBooks · doi:10.1007/978-88-470-0840-3_33 · Cited by 3
Heredity and Alzheimer's disease
Scott, W. K. (1998) · Current Opinion in Psychiatry · doi:10.1097/00001504-199807000-00010 · Cited by 2
Diagnosis of Dementia Using Nuclear Medicine Imaging Modalities
Merissa, N., Garrett, M., & Scott, P. J. H. (2011) · InTech eBooks · doi:10.5772/25283 · Cited by 2
Functional neuroimaging in Alzheimer's disease
Matsuda, H. (2006) · Radiation Medicine · doi:10.1007/s11604-006-2408-9 · Cited by 1
11 The Early Detection of Alzheimer's Disease with Positron Emission Tomography
Mistur, R. L., Mosconi, L., Switalski, R., Santi, S. D., Li, Y., Glodzik, L., Bryś, M., Tsui, W., Rusinek, H., & de Leon, M. J. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328875.003.0011 · Cited by 1
Chen, H., Qin, R., Luo, C., et al. (2020) · doi:10.21203/rs.3.rs-31270/v1 · Cited by 1
Les méthodes de la neuropsychologie
Baron, J. (2001) · Questions de personne · doi:10.3917/dbu.eusta.2001.01.0157
Manotas, M. R. (2009) · Gredos (University of Salamanca) · doi:10.14201/gredos.76537
Applications of fMRI to Neurodegenerative Disease
Mahmoud, S. Y., Jones, S. E., & Phillips, M. D. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0345-7_32
Stages of Brain Functional Failure in Alzheimer’s Disease
Rapoport, S. I. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-888-5_10
Functional imaging of Alzheimer's disease
Taler, V., & Saykin, A. J. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511782091.025
10 Neuroimaging in Alzheimer Disease
Kantarci, K., & Jack, C. R. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7777-9_10
13 Functional Imaging with FDG-PET in Mild Cognitive Impairment
Herholz, K. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328875.003.0013 · Cited by 1
Gárdián, G., Sas, K., Toldi, J., & Vécsei, L. (2009) · doi:10.1093/acprof:oso/9780195326697.003.0018
1 Introduction: Still More Questions than Answers
Jagust, W. J., & D’Esposito, M. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328875.003.0001
9 Genetics and Imaging in Alzheimer’s Disease
Bookheimer, S. Y. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328875.003.0009
Identifying stage-specific markers of Alzheimer's disease using quantitative proteomics
Yagensky, O. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7052
Raj, N., Singh, P. G., & Bv, S. (2021) · International Journal of Pharma and Bio Sciences · doi:10.22376/ijpbs.2021.12.2.b166-172
PPARγ Agonists for the Treatment of Alzheimer's Disease
Jiang, Q., Mandrekar, S., & Landreth, G. E. (2007) · Springer eBooks · doi:10.1007/7355_2007_014
(2006) · Steinkopff eBooks · doi:10.1007/3-7985-1604-9_7
Ainslie, P. N. (2014) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718270401.793490776
The functional imaging of dementia
Cappa, S. F., & Perani, D. (1996) · Neurocase · doi:10.1080/13554799608404028
Small Animal Imaging with Positron Emission Tomography
Cherry, S. R., & Kornblum, H. I. (2002) · Frontiers in neuroscience · doi:10.1201/9781420042153.ch9
Tai, Y., & Piccini, P. P. (2006) · Springer eBooks · doi:10.1007/1-84628-187-3_28
Metadata
- Authors
- Small, G. W.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Small, Gary W.
- ORCID
- Small, Gary W.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1995-03-22
- Volume
- 273
- Issue
- 12
- Pages
- 942
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2159538597
- Cited by
- 604
- References
- 52
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 5 · 2023: 12 · 2022: 7 · 2021: 16 · 2020: 15 · 2019: 9 · 2018: 12 · 2017: 15 · 2016: 16 · 2015: 7 · 2014: 14 · 2013: 15 · 2012: 18
- FWCI
- 27.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29mh046424-05)
- National Institute on Aging (AG05 128, AG 10123, P50AG005128, P30AG010123, U24AG021886)
- National Institute of Mental Health (1R29 MH46424)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- APOE ε4, familial Alzheimer's disease, brain glucose metabolism, left-right asymmetry, at-risk relatives, early Alzheimer's disease, neuroimaging biomarkers, genetic risk
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Analysis of Variance, Apolipoproteins E, Brain, Deoxyglucose, Family, Female, Fluorine Radioisotopes, Genotype, Glucose, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Models, Theoretical, Neuropsychological Tests, Risk Factors, Tomography, Emission-Computed, Fluorodeoxyglucose F18, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
